Shares of STAAR Surgical (NASDAQ: STAA) were down 9.6% on Thursday, according to data provided by S&P Global Market Intelligence, after announcing mixed quarterly results relative to Wall Street's expectations and lowering its near-term outlook.

To be sure, the implantable lens specialist saw net sales climb 14% year over year to $92.3 million in the second quarter -- slightly below estimates for sales of $93 million. On the bottom line, that translated to an adjusted net income of $19.7 million, or $0.40 per share (down from $0.42 per share a year earlier), handily exceeding estimates for earnings of $0.32 per share.

STAAR Surgical's revenue growth was driven entirely by 19% growth (20% at constant currency) in sales of its Implantable Collamer Lens (ICL) products to $93.1 million, offset partially by a $0.7 million sales reduction related to a sales return reserve of some intraocular lens (IOL) products. It seems revenue would have been roughly in line with expectations had it not been for that adjustment.

Continue reading

Source Fool.com